The president of the technical-scientific commission of Aifa Patrizia Popoli: “As with mRna vaccines, not originally tested against Omicron, you are protected from serious illness”
The vaccine of Novavax, approved yesterday by AIFA, will be available in Italy “starting from January” and it will be “an ideal tool for countries where it is difficult to maintain the cold chain” and “it is very easy to handle, to be kept in the fridge and for several months”. Patrizia Popoli, president of the technical-scientific commission of the Aifa drug agency, director of the ISS drug research and evaluation center, says this in an interview with Corriere della Sera.
According to Popoli, Novavax “has shown an efficacy of 90% in several large clinical studies, tested on 50,000 volunteers, 30,000 of whom have received the vaccine. It has also been tested on the elderly. The efficacy remains constant in the elderly. over 65. No worrying adverse events “. Regarding the protection from the omicron variant “the data refer to a population in which this variant did not circulate. We have seen that even with mRna vaccines, not originally tested against the new strain, one is protected from serious disease”.